Header Logo

Connection

ELIZABETH SHPALL to Combined Modality Therapy

Back to Details
This is a "connection" page, showing publications ELIZABETH SHPALL has written about Combined Modality Therapy.
ELIZABETH SHPALL
Connection Strength
0.597
Combined Modality Therapy
  1. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.
    View in: PubMed
    Score: 0.062
  2. Stem-cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol. 2004 Nov; 26(1-2):31-56.
    View in: PubMed
    Score: 0.026
  3. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clin Cancer Res. 2021 07 01; 27(13):3744-3756.
    View in: PubMed
    Score: 0.021
  4. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.021
  5. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020 10 08; 136(15):1786-1789.
    View in: PubMed
    Score: 0.020
  6. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2193-2205.
    View in: PubMed
    Score: 0.019
  7. High-dose chemotherapy for breast cancer. Cancer Treat Res. 2000; 103:77-114.
    View in: PubMed
    Score: 0.019
  8. Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant. 2000; 6(5):476-95.
    View in: PubMed
    Score: 0.019
  9. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557.
    View in: PubMed
    Score: 0.018
  10. Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. Hematol Cell Ther. 1999 Apr; 41(2):82-6.
    View in: PubMed
    Score: 0.018
  11. High-dose chemotherapy in gynecologic malignancies. Cancer Treat Res. 1998; 95:277-85.
    View in: PubMed
    Score: 0.016
  12. High-dose chemotherapy for the treatment of breast and ovarian cancer. Curr Opin Oncol. 1997 Mar; 9(2):122-5.
    View in: PubMed
    Score: 0.016
  13. Peripheral blood stem cells for autografting. Annu Rev Med. 1997; 48:241-51.
    View in: PubMed
    Score: 0.015
  14. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma. 2016 07; 57(7):1607-15.
    View in: PubMed
    Score: 0.014
  15. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Res. 1995 Dec 01; 55(23 Suppl):5921s-5924s.
    View in: PubMed
    Score: 0.014
  16. Shifting paradigms in the treatment of chronic lymphocytic leukemia. Future Oncol. 2015; 11(4):641-57.
    View in: PubMed
    Score: 0.013
  17. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leuk Lymphoma. 2015 Feb; 56(2):533-5.
    View in: PubMed
    Score: 0.013
  18. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood. 1994 Jun 01; 83(11):3132-7.
    View in: PubMed
    Score: 0.013
  19. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8.
    View in: PubMed
    Score: 0.012
  20. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun; 11(6):1132-43.
    View in: PubMed
    Score: 0.012
  21. New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation. Breast Cancer Res Treat. 1993; 26 Suppl:S19-23.
    View in: PubMed
    Score: 0.012
  22. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70.
    View in: PubMed
    Score: 0.011
  23. Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma. 2012 Mar; 53(3):499-502.
    View in: PubMed
    Score: 0.011
  24. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012 Apr; 18(4):584-92.
    View in: PubMed
    Score: 0.011
  25. Unrelated donor transplantation for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1067-71.
    View in: PubMed
    Score: 0.010
  26. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol. 1990 Sep; 38(3):386-91.
    View in: PubMed
    Score: 0.010
  27. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. Prog Clin Biol Res. 1990; 333:321-35; discussion 336.
    View in: PubMed
    Score: 0.009
  28. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 01; 115(9):1899-905.
    View in: PubMed
    Score: 0.009
  29. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23.
    View in: PubMed
    Score: 0.009
  30. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008 Jun; 14(6):672-84.
    View in: PubMed
    Score: 0.008
  31. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007 Jul 15; 110(2):340-4.
    View in: PubMed
    Score: 0.008
  32. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia. 2007 Dec; 21(12):2540-4.
    View in: PubMed
    Score: 0.008
  33. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006 Jun 15; 106(12):2664-71.
    View in: PubMed
    Score: 0.007
  34. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer. 2005 Oct 15; 104(8):1580-9.
    View in: PubMed
    Score: 0.007
  35. Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy. Am J Clin Oncol. 2005 Jun; 28(3):248-54.
    View in: PubMed
    Score: 0.007
  36. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecol Oncol. 2004 Jul; 94(1):98-106.
    View in: PubMed
    Score: 0.006
  37. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):707-18.
    View in: PubMed
    Score: 0.005
  38. Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft. Bone Marrow Transplant. 2001 Dec; 28(11):1083-6.
    View in: PubMed
    Score: 0.005
  39. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clin Cancer Res. 1999 Nov; 5(11):3425-31.
    View in: PubMed
    Score: 0.005
  40. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol. 1999 Oct; 17(10):3064-74.
    View in: PubMed
    Score: 0.005
  41. High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. Bone Marrow Transplant. 1999 Sep; 24(5):491-5.
    View in: PubMed
    Score: 0.005
  42. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res. 1999 Jul; 5(7):1731-7.
    View in: PubMed
    Score: 0.005
  43. Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant. Bone Marrow Transplant. 1999 Jun; 23(12):1323-4.
    View in: PubMed
    Score: 0.005
  44. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol. 1998 May; 16(5):1661-8.
    View in: PubMed
    Score: 0.004
  45. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone Marrow Transplant. 1997 Dec; 20(11):931-7.
    View in: PubMed
    Score: 0.004
  46. High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results. Bone Marrow Transplant. 1996 Sep; 18 Suppl 1:S26-9.
    View in: PubMed
    Score: 0.004
  47. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol. 1996 May; 14(5):1463-72.
    View in: PubMed
    Score: 0.004
  48. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. Cancer Chemother Pharmacol. 1996; 37(6):561-8.
    View in: PubMed
    Score: 0.004
  49. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. J Natl Cancer Inst. 1993 Jul 07; 85(13):1080-5.
    View in: PubMed
    Score: 0.003
  50. Myocardial ischemia associated with high-dose carmustine infusion. Cancer. 1991 Nov 01; 68(9):1910-2.
    View in: PubMed
    Score: 0.003
  51. The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. Prog Clin Biol Res. 1990; 338:121-8.
    View in: PubMed
    Score: 0.002
  52. High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. Cancer Chemother Pharmacol. 1990; 26(2):155-6.
    View in: PubMed
    Score: 0.002
  53. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol. 1989; 23(6):377-83.
    View in: PubMed
    Score: 0.002
  54. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988 Sep; 6(9):1368-76.
    View in: PubMed
    Score: 0.002
  55. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988 Apr 07; 318(14):869-76.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.